Yep, I think that's a very fair assessment. The other news (heart and renal) is very positive but it won't generate revenue in the short term so it's just putting more feathers in the bow at this point in time. Absolutely brilliant potential but that will take some time
to play out.
If Prevent is good then the SP should most definitely have a huge leap and then revenue should increase once insurers are forced to accept that the study has a meaningful impact on patient outcomes. A positive Prevent study pretty much ensures this if my understanding is correct.
Getting closer..... only a few more weeks.
Yep, I think that's a very fair assessment. The other news...
Add IPD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.3¢ |
Change
-0.002(2.11%) |
Mkt cap ! $188.1M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.3¢ | 9.3¢ | $118.4K | 1.210M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 78801 | 9.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.6¢ | 3900 | 1 |
View Market Depth
| Last trade - 15.59pm 19/04/2024 (20 minute delay) ? |
|
|||||
|
Last
9.3¢ |
Change
-0.002 ( 6.06 %) |
||||
| Open | High | Low | Volume | ||
| 9.6¢ | 10.0¢ | 9.3¢ | 351462 | ||
| Last updated 15.55pm 19/04/2024 ? | |||||
| IPD (ASX) Chart |